Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 51, Issue 24, Pages 7968-7979Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm800964f
Keywords
-
Categories
Funding
- Portuguese Fundacao para a Ciencia e Tecnologia [SFRH/BPD/29874/2006, PDCT/QUI/56985/2004]
- Fondazione Monte dei Paschi di Siena
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/29874/2006, PDCT/QUI/56985/2004] Funding Source: FCT
Ask authors/readers for more resources
Matrix metalloproteinases (MMPs) and carbonic anhydrases (CAs) are two classes of zinc enzymes with different roles and catalytic targets, such as the degradation of most of the extracellular matrix (ECM) proteins and the regulation of the CO2/HCO3- equilibrium in the cells, respectively. Both families have isoforms which were proved to be involved in several stages of carcinogenic processes, and so the selective inhibition of these enzymes might be of interest in cancer therapy. We report herein the design, synthesis, and in vitro evaluation of a series Of Compounds possessing the iminodiacetic acid as the main backbone and two functional groups attached, namely, the hydroxamic acid and the arylsulfonamide (ArSO2NH2) moieties, to enable the inhibition of MMPs and CAs, respectively. These compounds were demonstrated to strongly inhibit both MMPs and CAs, some of them from the nanomolar to subnanomolar range. Furthermore, a docking study for MMPs was reported for the most promising compound in order to investigate its binding interactions with the different MMPs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available